Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. director and co-founder Jonathan Sheena sold 109 shares of Common Stock on 2026-08-03 at $267.9893 per share. The sale was effected to satisfy tax withholding and remittance obligations arising from the vesting of RSUs and was carried out pursuant to a written instruction intended to meet the affirmative defense conditions of Rule 10b5-1(c), contained in a Stock Unit Agreement granted on January 31, 2025. Following the sale, Sheena held 245,614 shares directly. Separate holdings of 18,032 shares each are reported for the Caraluna 1 Trust and Caraluna 2 Trust for the benefit of trust beneficiaries, with Sheena disclaiming beneficial ownership of those securities.
Natera, Inc. associated filer Michael Brophy filed a notice to sell common stock. The planned sale covers 478 shares of common stock, valued at $129,232.08, to be sold through Morgan Stanley Smith Barney LLC on or about 08/04/2026 on NASDAQ. These shares relate to Restricted Stock Units acquired from the issuer on 07/31/2026.
The filing also lists recent sales over the prior three months, including individual transactions of 317 shares for $84,952.61 on 07/31/2026 and 1,863 shares for $464,594.94 on 07/29/2026, some executed under a 10b5-1 Sales Plan.
Natera, Inc. affiliate Jonathan Sheena filed a notice to sell common stock. The filing covers a proposed sale of 108 shares of common stock listed on NASDAQ, with an aggregate market value of $28,918.08, expected on 08/03/2026. It also notes 3,549 Restricted Stock Units granted on 01/31/2025 for services rendered, and lists several prior common stock sales over the past three months.
Matthew Rabinowitz filed a notice to sell shares of common stock of issuer NTRA. The planned sale covers 29,345 shares underlying Restricted Stock Units acquired on 01/31/2025 for services rendered. The filing also lists several common stock sales over the past three months, including 50,000-share transactions in June 2026.
Natera, Inc. insider Daniel Rabinowitz has filed a notice of intent to sell common stock. The filing lists a proposed sale of 330 shares of common stock through a brokerage firm on 08/03/2026 on the NASDAQ, with an indicated value of $88,360.80.
The notice also reports that Rabinowitz previously acquired 10,353 shares on 01/31/2025 as restricted stock units for services rendered. In the past three months, he reported sales of 33,600 shares on 06/24/2026 for $8,455,352.64, 16,800 shares on 07/01/2026 for $4,574,430.00, 884 shares on 07/27/2026 for $230,273.85, and 1,003 shares on 07/28/2026 for $254,832.63.
Natera, Inc. insider Solomon Moshkevich filed to sell common stock under a notice of proposed sale. The plan covers up to 12,720 shares of common stock, expected to be sold on or after 07/31/2026. These shares were acquired as Restricted Stock Units from the issuer on 01/31/2025 in consideration for services rendered. The filing also lists recent sales of common stock, including 3,000 shares on 07/01/2026 for $818,710.50 and 3,000 shares on 06/01/2026 for $655,294.78.
Natera, Inc. shareholder John Fesko filed a notice to sell common stock under Rule 144. The planned transaction covers 292 shares of common stock on or after August 3, 2026, to be sold on NASDAQ with an indicated value of $78,185.92.
The filing also lists 11,832 Restricted Stock Units granted on January 31, 2025 for services rendered. In the preceding three months, Fesko reported four open-market sales of Natera common stock: 931 shares for $236,539.62 on July 28, 2026, 782 shares for $203,703.79 on July 27, 2026, 1,438 shares for $291,683.56 on May 26, 2026, and 291 shares for $59,992.56 on May 1, 2026.
An affiliate of the issuer filed a Form 144 covering a proposed sale of 1,167 shares of common stock on NASDAQ with an aggregate market value of $312,475.92, identified under CUSIP 143215382. The filer previously received 36,682 Restricted Stock Units on January 31, 2025 as compensation for services rendered.
In the preceding three months, the same reporting person sold multiple blocks of common stock, including 41,124 shares for $9,089,777.54 on June 4, 2026 and additional smaller transactions in April, May, July 2026.
Michael Brophy filed to potentially sell 313 shares of common stock of ETrade Corporation on or after 08/03/2026 on NASDAQ. The planned sale relates to stock previously acquired from 12,720 Restricted Stock Units granted for services on 01/31/2025. In the prior three months, Brophy reported several sales of common stock, including 1,863 shares on 07/29/2026 and additional sales on 07/28/2026, 07/27/2026, and 05/04/2026.
An affiliate of Steven L. Chapman filed a Form 144 indicating an intent to sell 1,894 shares of common stock on or after 08/03/2026 on the NASDAQ, with an aggregate market value of $502,667.60. The filing also lists recent sales of common stock, including 41,124 shares on 06/04/2026 for $9,089,777.54 and additional smaller trades on 05/04/2026, 07/27/2026, and 07/28/2026.